- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.12.24 | Why is colorectal cancer rising in younger age groups? | ||
| 12.12.24 | Lynparza boosts long-term survival in early breast cancer | ||
| 12.12.24 | Price deal opens door to NHS use of Santhera DMD drug | ||
| 11.12.24 | Lilly adds another sales channel for obesity drug Zepbound | ||
| 11.12.24 | Mulvany hits the reset button at BenevolentAI | ||
| 11.12.24 | Refiling for cALD therapy on the cards after new data | ||
| 11.12.24 | Drug-digital dual therapy for depression starts phase 2 | ||
| 11.12.24 | Bausch + Lomb dips on rumour of failing takeover talks | ||
| 11.12.24 | uniQure rockets on map to market for Huntington's therapy | ||
| 10.12.24 | ASH: Stem cell transplant study exposes US zip-code lottery | ||
| 10.12.24 | ConTIPI starts rollout of pelvic organ prolapse device in US | ||
| 10.12.24 | MSD gets first positive trial of Keytruda/Lynparza combo | ||
| 10.12.24 | ASH: Blenrep ups survival by 42% in multiple myeloma trial | ||
| 10.12.24 | Suspect in UnitedHealth CEO killing charged with murder | ||
| 09.12.24 | Fresh from IPO, obesity drug developer BioAge hits a hurdle | ||
| 09.12.24 | ASH: Regeneron plays its PNH hand | ||
| 09.12.24 | ASH: MSD's ROR1 drug hits the target in first-line lymphoma | ||
| 09.12.24 | Novo's $16.5bn Catalent deal cleared by EU Commission | ||
| 09.12.24 | Relief for Chinese biotechs as BIOSECURE Act delayed | ||
| 06.12.24 | Lilly invests another $3bn in its manufacturing network | ||
| 06.12.24 | GSK builds neuro, cancer pipeline with trio of deals | ||
| 06.12.24 | A single mutation could make H5N1 flu a human threat | ||
| 06.12.24 | Insulin pump firm Insulet wins $452m in trade secrets clash | ||
| 06.12.24 | Atlas closes $450m biotech fund, and other financing news | ||
| 05.12.24 | FDA clears AZ's Imfinzi for aggressive lung cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
